Harbin Pharmaceutical Group released its 2026 interim report. Total operating revenue was 8.296 billion yuan, up 2.10% year on year, and net profit attributable to the parent company was 410 million yuan, up 57.99% year on year. Net cash flow from operating activities was negative 46.2668 million yuan, an increase of 94.9733 million yuan compared with the same period last year. The asset-liability ratio was 52.96%, down 1.75 percentage points from a year earlier. Gross margin was 26.38%, up 2.27 percentage points from the previous quarter. Return on equity was 6.72%, up 2.09 percentage points year on year. Diluted earnings per share were 0.16 yuan, up 58.00% year on year. Total asset turnover was 0.57 times, up 1.11% year on year. The number of shareholders was 109,800, and the top ten shareholders held 51.80% of total share capital.
Harbin Pharmaceutical Group Co LtdNet profit up 57.99% year on year, with improved margins and ROE.
